^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

COMPANY:
MiRXES

i
Other names: MiRXES | MiRXES Pte Ltd
Related tests:
Evidence

News

8ms
Singapore’s Mirxes inks agreements for cancer early detection tests in China, Indonesia (Genomeweb)
"Mirxes...this week that it has recently signed two agreements that will help advance the company's commercial push into China and Indonesia. Earlier this month Mirxes inked a memorandum of understanding with Zhejiang Anji Economic Development District that outlines a path for Mirxes to scale up its cancer early detection blood tests in China."
Licensing / partnership
8ms
Mirxes receives FDA’s Breakthrough Device Designation for GASTROClearTM to advance blood-based cancer early detection (Mirxes Press Release)
"Mirxes Corporation USA, the wholly owned subsidiary of Mirxes Pte Ltd...announced today that its flagship product GASTROClearTM, a PCR-based in vitro diagnostic test for early detection of gastric (stomach) cancer, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA)."
FDA event
|
GASTROClear Test
9ms
MiRxes gets $50M in Series D funding, applies to Hong Kong Limited stock exchange (Genomeweb)
"MiRxes said Wednesday that it has completed a Series D funding round totaling $50 million, which will help accelerate the Singapore-based firm's development of cancer early detection blood tests and other preventive healthcare solutions."
Financing
|
GASTROClear Test
over1year
MiRxes, PT Elion to develop cancer tests for Indonesian population (Genomeweb)
"Singaporean biotechnology firm MiRxes said on Tuesday that it has reached an agreement with PT Elion Medika Indonesia to develop blood-based tests for the early detection of multiple cancers for the Indonesian market...As part of the arrangement, PT Elion will validate MiRxes' microRNA-based tests for stomach and lung cancer in an Indonesian cohort. The two companies have also established a joint project for creating a multi-cancer blood test based on miRNA and DNA methylation biomarkers found in Indonesian cancer patients."
Licensing / partnership
almost2years
MirXes, Singapore Healthcare organizations partner to develop multi-cancer early detection test (Genomeweb)
"MirXes...said on Thursday it has signed a memorandum of understanding with several Singapore universities and hospitals to launch a study of circulating microRNA and DNA methylation biomarkers for multi-cancer early detection...Under Project CADENCE (cancer detected early can be cured), the partners plan to discover and validate methylation biomarkers to develop a blood-based test for up to nine cancer types, including lung, breast, colorectal, liver, and pancreatic cancer."
Licensing / partnership